KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to -$180.0 million.

  • Amgen's Change in Accured Expenses rose 3454.55% to -$180.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478.0 million, marking a year-over-year increase of 235.55%. This contributed to the annual value of $92.0 million for FY2024, which is 9034.63% down from last year.
  • Amgen's Change in Accured Expenses amounted to -$180.0 million in Q3 2025, which was up 3454.55% from $804.0 million recorded in Q2 2025.
  • In the past 5 years, Amgen's Change in Accured Expenses ranged from a high of $1.1 billion in Q4 2023 and a low of -$1.1 billion during Q1 2024
  • In the last 5 years, Amgen's Change in Accured Expenses had a median value of -$180.0 million in 2025 and averaged $29.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 48750.0% in 2021, then soared by 32323.23% in 2022.
  • Over the past 5 years, Amgen's Change in Accured Expenses (Quarter) stood at -$267.0 million in 2021, then plummeted by 141.57% to -$645.0 million in 2022, then skyrocketed by 271.01% to $1.1 billion in 2023, then tumbled by 34.0% to $728.0 million in 2024, then plummeted by 124.73% to -$180.0 million in 2025.
  • Its last three reported values are -$180.0 million in Q3 2025, $804.0 million for Q2 2025, and -$874.0 million during Q1 2025.